EC
STLN

EntryPoint Capital’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

EntryPoint Capital’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.2K Buy
23,852
+5,396
+29% +$16.5K 0.02% 717
2025
Q4 		$65.7K Buy
+18,456
New +$68.5K 0.03% 625

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EntryPoint Capital's STLN Position: Q1 2026 in Review

EntryPoint Capital increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 29% in Q1 2026, buying an estimated $16.5K and bringing the position to 23,852 shares worth $73.2K. The position accounts for 0.02% of the portfolio, ranked #717.

EntryPoint Capital first reported a position in STLN in Q4 2025 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • EntryPoint Capital held 23,852 shares of Starling Oncology Institute, Inc. Common Stock worth $73.2K as of Q1 2026.
  • EntryPoint Capital bought 5,396 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $16.5K.
  • Starling Oncology Institute, Inc. Common Stock made up 0.02% of EntryPoint Capital's portfolio in Q1 2026, its #717 holding.
  • EntryPoint Capital first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2025 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.